Clinical outcomes by MZL subtype and prior therapies
| Outcome . | MZL subtype . | Prior therapy . | Total (n = 60) . | |||
|---|---|---|---|---|---|---|
| Splenic (n = 13) . | Nodal (n = 17) . | Extranodal (n = 30) . | RTX (n = 16) . | RTX-CIT (n = 39) . | ||
| Median time to initial response (range), mo | 2.8 (2.8-8.4) | 16.6 (2.7-22.4) | 5.6 (2.4-19.4) | 2.8 (2.4-19.4) | 5.6 (2.7-22.4) | 5.6 (2.4-22.4) |
| 33-mo DOR, % (95% CI) | NR (NE to NE) | NR (NE to NE) | 50 (24.5-70.5) | NR (NE to NE) | 47 (24.4-67.3) | 48 (28.8-65.4) |
| 33-mo PFS, % (95% CI) | 42 (15.2-66.5) | 24 (6.5-46.6) | 32 (13.2-52.1) | 32 (6.4-61.5) | 30 (15.8-45.7) | 32 (19.3-45.3) |
| 33-mo OS, % (95% CI) | 66 (32.0-85.8) | 69 (40.5-85.6) | 76 (56.5-87.9) | 75 (46.3-89.8) | 76 (58.1-86.5) | 72 (58.4-81.9) |
| Outcome . | MZL subtype . | Prior therapy . | Total (n = 60) . | |||
|---|---|---|---|---|---|---|
| Splenic (n = 13) . | Nodal (n = 17) . | Extranodal (n = 30) . | RTX (n = 16) . | RTX-CIT (n = 39) . | ||
| Median time to initial response (range), mo | 2.8 (2.8-8.4) | 16.6 (2.7-22.4) | 5.6 (2.4-19.4) | 2.8 (2.4-19.4) | 5.6 (2.7-22.4) | 5.6 (2.4-22.4) |
| 33-mo DOR, % (95% CI) | NR (NE to NE) | NR (NE to NE) | 50 (24.5-70.5) | NR (NE to NE) | 47 (24.4-67.3) | 48 (28.8-65.4) |
| 33-mo PFS, % (95% CI) | 42 (15.2-66.5) | 24 (6.5-46.6) | 32 (13.2-52.1) | 32 (6.4-61.5) | 30 (15.8-45.7) | 32 (19.3-45.3) |
| 33-mo OS, % (95% CI) | 66 (32.0-85.8) | 69 (40.5-85.6) | 76 (56.5-87.9) | 75 (46.3-89.8) | 76 (58.1-86.5) | 72 (58.4-81.9) |
NR, not reached.